UPDATE: Anteris Technologies Global Corp (ASX: AVR) is witnessing an extraordinary surge in its stock value, skyrocketing by over 50% after the company successfully closed a massive $320 million capital raise. The announcement was made just moments ago, sending shares to a new high of $9.40 each.
This substantial funding, achieved through the issuance of new shares priced at $5.75, will boost Anteris’s market capitalization by more than 60%. In a remarkable twist, this capital increase surpasses the company’s current ASX valuation of $370 million and its NASDAQ listing of $394 million.
Key to this funding round is the strategic investment from Medtronic Plc (NASDAQ: MDT), the world’s largest medical technology company, which contributed $90 million. Anteris has expressed confidence that this partnership will reshape the Transcatheter Aortic Valve Replacement (TAVR) market by enhancing clinical science and valve design, while prioritizing patient outcomes.
Anteris’s CEO, Wayne Paterson, described this investment as a critical endorsement of the company’s strategic direction. “This strategic investment, along with our underwritten offering of common stock, represents an important milestone for our company,” he stated. The collaboration could potentially expand into other strategic areas in the future, enhancing Anteris’s reach and capabilities.
The funds raised will primarily support the ongoing Paradigm clinical trial, which is assessing the efficacy of Anteris’s DurAVR THV System compared to existing TAVR devices for treating patients with severe aortic stenosis. This clinical trial is pivotal for Anteris as it seeks regulatory approval for its innovative product designed to significantly improve patient outcomes.
Medtronic’s Vice President, Jorie Sokin, highlighted Anteris’s pioneering role in the TAVR sector. “Our investment in differentiated innovation like the DurAVR THV technology — which has the potential to offer improved valve performance — is core to our commitment to define and drive the future of TAVR,” Sokin noted, emphasizing the importance of meeting the needs of patients and healthcare teams alike.
Founded in Australia, Anteris has established a strong presence in Minneapolis, employing a team of experienced professionals dedicated to delivering restorative solutions for structural heart disease patients.
With shares currently trading 5.5% higher at $9.40, the market is reacting positively to this news. Investors are keenly watching how this capital raise will propel Anteris into its next phase of growth and innovation.
Stay tuned for further updates as this story develops and the market continues to respond. Don’t miss out on what could be a pivotal moment for Anteris Technologies and the TAVR landscape!
